Results of lenvatinib as first-line targeted therapy for advanced hepatocellular cancer: a retrospective study
- Authors: Antonova E.Y.1, Janyan I.A.1, Laktionov K.K.1,2, Pogrebnyakov I.V.1, Savchenko I.V.1, Breder V.V.1
-
Affiliations:
- Blokhin National Medical Research Center of Oncology
- Pirogov Russian National Research Medical University
- Issue: Vol 27, No 2 (2025)
- Pages: 144-148
- Section: Articles
- URL: https://journal-vniispk.ru/1815-1434/article/view/313833
- DOI: https://doi.org/10.26442/18151434.2025.2.203293
- ID: 313833
Cite item
Full Text
Abstract
Background. Hepatocellular carcinoma (HCC) is one of the most aggressive tumor diseases, with an annual increase in morbidity and mortality. Therefore, the studies for effective treatment options is crucial. The evolution of HCC treatment and the priority of immunotherapy in the first line of advanced HCC leave questions about the place and effectiveness of tyrosine kinase inhibitors in the first line of antitumor therapy.
Aim. This study evaluated the efficacy and tolerability of lenvatinib in patients in the first line treatment advanced HCC in real clinical practice.
Materials and methods. The retrospective study included 41 patients who received targeted therapy with lenvatinib as the first line for unresectable HCC in medical institutions of the Russian Federation and were observed at Blokhin National Medical Research Center of Oncology.
Results. The median progression-free survival in patients treated with lenvatinib was 13.9 months. The median overall survival (OS) was 27.3 months. One-year OS was 80%. Two-year OS was 56%. The best response to treatment in our study was stabilization in 67% of cases, and disease progression during therapy was observed in 23% of cases, assessed using mRECIST.
Conclusion. In a selected cohort of patients with advanced HCC, tyrosine kinase inhibitors (in particular lenvatinib) was studied and the efficacy of lenvatinib treatment was demonstrated in key survival indicators in the first line of HCC therapy in real clinical practice. There was also a low incidence of adverse events leading to discontinuation of therapy and dose reduction.
Full Text
##article.viewOnOriginalSite##About the authors
Elena Yu. Antonova
Blokhin National Medical Research Center of Oncology
Author for correspondence.
Email: elenaantonova5@mail.ru
ORCID iD: 0000-0002-9740-3839
SPIN-code: 6335-7053
Cand. Sci. (Med.), Oncologist
Russian Federation, MoscowIrina A. Janyan
Blokhin National Medical Research Center of Oncology
Email: elenaantonova5@mail.ru
ORCID iD: 0000-0002-6323-511X
Surgeon
Russian Federation, MoscowKonstantin K. Laktionov
Blokhin National Medical Research Center of Oncology; Pirogov Russian National Research Medical University
Email: elenaantonova5@mail.ru
ORCID iD: 0000-0003-4469-502X
SPIN-code: 7404-5133
D. Sci. (Med.), Prof.
Russian Federation, Moscow; MoscowIgor V. Pogrebnyakov
Blokhin National Medical Research Center of Oncology
Email: elenaantonova5@mail.ru
ORCID iD: 0000-0002-4587-4153
SPIN-code: 2533-4861
Cand. Sci. (Med.), Head of Department
Russian Federation, MoscowIlya V. Savchenko
Blokhin National Medical Research Center of Oncology
Email: elenaantonova5@mail.ru
ORCID iD: 0000-0003-2142-661X
Oncologist
Russian Federation, MoscowValery V. Breder
Blokhin National Medical Research Center of Oncology
Email: elenaantonova5@mail.ru
ORCID iD: 0000-0002-6244-4294
SPIN-code: 9846-4360
D. Sci. (Med.), Head of Department
Russian Federation, MoscowReferences
- Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021;71(3):209-49. doi: 10.3322/caac.21660
- Бредер В.В., Базин И.С., Балахнин П.В., и др. Злокачественные опухоли печени и желчевыводящей системы. Практические рекомендации RUSSCO, часть 1.1. Злокачественные опухоли. 2024;14(3s2):358-403
- Finn RS, Qin S, Ikeda M, et al. Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma. N Engl J Med. 2020;382(20):1894-905. doi: 10.1056/NEJMoa1915745
- Sangro B, Chan SL, Kelley RK, et al. Four-year overall survival update from the phase III HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma. Ann Oncol. 2024;35(5):448-57. doi: 10.1016/j.annonc.2024.02.005
- Kudo M, Yau T, Decaens T, et al. Nivolumab (NIVO) plus ipilimumab (IPI) vs lenvatinib (LEN) or sorafenib (SOR) as first-line (1L) therapy for unresectable hepatocellular carcinoma (uHCC): CheckMate 9DW expanded analyses. JCO. 2025; 43(4_suppl):520-2. doi: 10.1200/jco.2025.43.4_suppl.520
- Llovet JM, Kudo M, Merle P, et al. Lenvatinib plus pembrolizumab versus lenvatinib plus placebo for advanced hepatocellular carcinoma (LEAP-002): a randomised, double-blind, phase 3 trial. Lancet Oncol. 2023;24(12):1399-410. doi: 10.1016/S1470-2045(23)00469-2
- Wu CJ, Lee PC, Hung YW, et al. Lenvatinib plus pembrolizumab for systemic therapy-naive and -experienced unresectable hepatocellular carcinoma. Cancer Immunol Immunother. 2022;71(11):2631-63. doi: 10.1007/s00262-022-03185-6
- Kudo M, Finn RS, Qin S, et al. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. Lancet. 2018;391(10126):1163-13. doi: 10.1016/S0140-6736(18)30207-1
- Welland S, Leyh C, Finkelmeier F, et al. Real-World Data for Lenvatinib in Hepatocellular Carcinoma (ELEVATOR): A Retrospective Multicenter Study. Liver Cancer. 2022;11(3):219-32. doi: 10.1159/000521746
- Петкау В.В., Султанбаев А.В., Меньшиков К.В., и др. Ленватиниб у пациентов с нерезектабельной гепатоцеллюлярной карциномой в реальной клинической практике. Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2022;32(4):75-88 [Petkau VV, Sultanbaev AV, Menshikov KV, et al. Lenvatinib Therapy in Patients with Unresectable Hepatocellular Carcinoma in Real Clinical Practice. Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2022;32(4):75-88 (in Russian)]. doi: 10.22416/1382-4376-2022-32-4-75-88
- Persano M, Rimini M, Tada T, et al. Sequential therapies after atezolizumab plus bevacizumab or lenvatinib first-line treatments in hepatocellular carcinoma patients. Eur J Cancer. 2023;189:112933. doi: 10.1016/j.ejca.2023.05.021
- Furuse J, Izumi N, Motomura K, et al. Long-Term Survival of Patients with Unresectable Hepatocellular Carcinoma Treated with Lenvatinib in Real-World Clinical Practice. Cancers (Basel). 2025;17(3):479. doi: 10.3390/cancers17030479
Supplementary files
